AlphaMadera's AlphaVal page computes Acacia Research Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ACTG as undervalued, fairly valued, or overvalued.

What is Acacia Research Corporation's fair value?

Fair value for ACTG is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ACTG?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ACTG's most recent reported fundamentals.

ACTG - Acacia Research Corporation

Price: -- -- | CONSENSUS: Buy DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Strong

Trading 83.4% below fair value

Current Price $4.66

Bear Case $16.44 252.9% upside ($16.44 - $4.66) / $4.66 = 252.9% 12% stage 1 growth, 11% discount

Fair Value $28.06 502.2% upside ($28.06 - $4.66) / $4.66 = 502.2% 20% stage 1 growth, 11% discount

Bull Case $42.66 815.4% upside ($42.66 - $4.66) / $4.66 = 815.4% 26% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

20.0%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (20% base case)

Terminal Value % of EV 46%

Implied Market Multiple 4.1x

Plain-Language Summary

Using a two-stage FCF DCF with 20% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $28.06 per share.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions